Table 3.
Risk factors for OS by univariate and multiple Cox proportional hazards regression analysis
| Univariate Multivariate | ||||
|---|---|---|---|---|
| Parameters | HR(95%CI) | p value | HR(95%CI) | p value |
| Age (high vs low) | 1.13(0.57–2.17) | 0.587 | ||
| Gender (male vs female) | 1.49(0.76–2.78) | 0.224 | ||
| Current smokers (yes vs no) | 1.11(0.60–1.97) | 0.754 | ||
| Alcohol (yes vs no) | 1.42(0.75–2.55) | 0.215 | ||
| Diabetes (yes vs no) | 1.78(0.61–4.45) | 0.287 | ||
| Hypertension (yes vs no) | 1.14(0.53–2.51) | 0.678 | ||
| ECOG PS (0 vs ≥1) | 0.88(0.45–1.61) | 0.612 | ||
| Tumor size (T1/T2 vs T3/T4) | 1.67(0.92–3.15) | 0.089 | 1.88(0.92–3.58) | 0.073 |
| Lymph node (N0 vs N1–3) | 1.92(0.87–3.98) | 0.142 | ||
| Metastasis stage (M0 vs M1a/b) | 2.06(1.07–3.88) | 0.024* | 1.73(0.90–2.92) | 0.093 |
| Differentiation (Well/moderate vs poor) | 1.55(1.04–2.36) | 0.041* | 1.22(0.81–1.72) | 0.312 |
| Histology (AC vs non-AC) | 1.24(0.70–2.14) | 0.412 | ||
| Chemotherapy (DP vs AP/GP) | 1.43(0.88–2.45) | 0.126 | ||
| CRP (high vs low) | 1.39(0.78–2.43) | 0.244 | ||
| AFR (≤8.02 vs > 8.02) | 1.93(1.28–2.98) | 0.011* | 1.79(1.11–2.59) | 0.029* |
NSCLC Non–small cell lung cancer, ECOG PS Eastern cooperative oncology group performance status, TNM Tumor–node–metastasis, SCC Squamous carcinoma, AC Adenocarcinoma, DP Docetaxel combined with platinum, AP Pemetrexed combined with platinum, GP Gemcitabine combined with platinum, CRP C-reactive protein, AFR Albumin-to-fibrinogen ratio, OS Overall survival, HR Hazard ratio, CI Confidence interval. *P < 0.05